9.3.0.0 Pe­ri­op­er­a­tive Care

Many stan­dards for pe­ri­op­er­a­tive care lack a ro­bust ev­i­dence base. How­ev­er, the fol­low­ing ap­proach (69) may be con­sid­ered:

1.Tar­get glu­cose range for the pe­ri­op­er­a­tive pe­ri­od should be 80–180 mg/dL (4.4–10.0 mmol/‍L).

2.Per­form a pre­op­er­a­tive risk as­sess­ment for pa­tients at high risk for is­chemic heart dis­ease and those with au­to­nom­ic neu­ropa­thy or renal fail­ure.

3.With­hold met­formin the day of surg­ery.

4.With­hold any other oral hy­po­glycemic agents the morn­ing of surg­ery or pro­ce­dure and give half of NPH dose or 60–80% doses of long-‍act­ing ana­log or pump basal in­sulin.

5.Mon­i­tor blood glu­cose at least every 4–6 h while NPO and dose with short-‍ or rapid-‍acting in­sulin as need­ed.

A re­view found that pe­ri­op­er­a­tive glycemic con­trol tighter than 80– 180 mg/dL (4.4–10.0 mmol/‍L) did not im­prove out­comes and was as­so­ci­at­ed with more hy­po­glycemia (70); there­fore, in gen­er­al, tighter glycemic tar­gets are not ad­vised. A re­cent study re­port­ed that, com­pared with the usual in­sulin dose, on av­er­age an ap­prox­i­mate 25% re­duc­tion in the in­sulin dose given the evening be­fore surg­ery was more like­ly to achieve pe­ri­op­er­a­tive blood glu­cose lev­els in the tar­get range with de­creased risk for hy­po­glycemia (71).

In non­car­diac gen­er­al surg­ery pa­tients, basal in­sulin plus pre­meal short-‍ or rapid-‍acting in­sulin (basal-‍bolus) cov­er­age has been as­so­ci­at­ed with im­proved glycemic con­trol and lower rates of pe­ri­op­er­a­tive com­pli­ca­tions com­pared with the tra­di­tion­al slid­ing scale reg­i­men (short-‍ or rapid-‍acting in­sulin cov­er­age only with no basal in­sulin dos­ing) (38,72).